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Abstract  
Sarcoidosis is a multisystemic disorder of unknown etiology which is characterized by the formation of non-caseating granulomas in involved 
tissues. Cardiac involvement is one of the least common manifestations and it can occur at any point of time during the course of sarcoidosis. Here 
we present the case of 2 patients with known sarcoidosis who develop cardiac abnormalities in the absence of known primary cardiac cause. In our 
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Sarcoidosis, an enigmatic multisystemic disease, is characterized by 
the formation of granulomas in many tissues mainly the lungs, the 
lymphoreticular system, the eyes, and the skin, with cardiac 
involvement being a rare entity [1]. Many reports showed that the 
quoted incidence of heart involvement in sarcoidosis in their review 
was around 2%, so that it was one of the least common 
manifestations [1]. The clinical sequelae of cardiac sarcoidosis vary 
from asymptomatic conduction abnormalities to heart failure, fatal 
ventricular arrhythmias, and sudden death. Foregoing data, early 
diagnosis and prompt treatment are essential since they can 
improve prognosis [2] by reducing the chances of sudden death.  
  
  
Patient and observation 
 
Case 1  
  
A 40-year-old Tunisian woman, with a history of diabetes mellitus in 
diet and Lofgren's syndrome (an acute presentation consisting of 
polyarthralgia, erythema nodosum, bilateral intrathoracic 
lymphadenopathies) diagnosed in February 2013, came to our 
department, in February 2014, for exploration of exertional dyspnea 
of one month evolution and progressively worsening without fever, 
chest pain, or syncope. The patient denied any past history of 
hypertension, coronary artery, or thyroid disease. She did not 
smoke or consume alcohol. On physical examination, she was 
conscious, cooperative, and afebrile. She was hemodynamically 
stable (blood pressure (BP) 130/70 mmHg and had a regular pulse 
of 88 beats /minute.). She had good color and was slightly 
polypneic with no peripheral cyanosis (peripheral oxygen saturation 
97%). She presented no palpable adenopathy or signs of jugular 
distension. Cardiac auscultation revealed rhythmic sounds with no 
murmur or friction rub.There were no signs of peripheral edema or 
deep vein thrombosis. Pulmonary, abdominal, and neurological 
examination revealed no abnormalities. The admission 
electrocardiogram (ECG) was normal. On investigation, blood 
biochemistry, liver, renal function, thyroid function and, hemogram 
showed no abnormalities except lymphopenia. Her angiotensin 
converting enzyme (ACE) level was 132 units (normal range < 
68units). The immunological markers were negative. A contrast-
enhanced computed tomography (CT) chest scan showed almost 
complete regression of mediastinal lymphadenopathies without 
pleuroparenchymal lesion. Respiratory functional tests and 
bronchoscopy with transbronchial lung biopsy were normal. The 
transthoracic echocardiography with Doppler showed abnormal left 
ventricular relaxation and systolic dysfunction of the left ventricle 
with ventricular ejection fraction (EF) of 40%. In the light of these 
symptoms and echocardiographic abnormalities, for which other 
possible causes have been excluded, the diagnosis of sarcoidosis 
with heart involvement was suspected. Thus, more specialized 
cardiac evaluation was needed. 24 hour holter monitoring showed 
recurrent episodes of 2000 monomorphic ventricular extrasystoles. 
Cardiac magnetic resonance imaging (MRI) with gadolinium contrast 
showed evidence of delayed hyper enhancement in both the basal 
and inferolateral left ventricular regions, suspicious for 
fibrogranulomatous tissue of sarcoidosis (Figure 1). The left 
ventricular ejection fraction was 40%. Laboratory tests confirmed 
negative serial markers of myocardial necrosis. Technetium99m 
sestamibi scintigraphy myocardial perfusion study showed 
decreased uptake in the inferolateral and apical ventricular 
myocardium, which was reversible during stress (reverse 
distribution) (Figure 2). Coronary angiography and let 
ventriculography showed angiographically normal coronary arteries. 
Considering all these clinical and investigatioanal findings in a 
patient with a history of Lofgren's syndrome and in the absence of 
primary heart disease, the diagnosis of cardiac sarcoidosis was 
made. The patient started with a dose of 1mg/kg/day of 
corticosteroids in addition to supportive care. This dose was tapered 
gradually to a maintenance level of 15 mg per day over 5 months. 
To this day, evolution was favorable.  
  
Case 2  
  
A 48-year-old Tunisian woman, presented to our consultations with 
a history of intermittent palpitations and exertional dyspnea of 4 
months duration, progressively worsening for 2 weeks before, 
without any history of chest pain or syncope. She had a past history 
of systemic sarcoidosis diagnosed in April 2009 on the basis of the 
following compatible clinical and radiologic findings: systemic 
symptoms (such as fatigue, anorexia, and weight loss), parotid 
enlargement, negative tuberculin skin test, lymphopenia, 
hypercalciuria, increased serum ACE level, intrathoracic 
lymphadenopathies which were hilar (Figure 3), bilateral 
symmetrical, and associated with right paratracheal window lymph 
node involvement. Pulmonary functions tests demonstrated 
decreased volumes and CO diffusing capacity. Lymphocytosis in 
broncho-alveolar lavage was observed and a CD4+/CD8+ 
lymphocyte ratio was greater than 3.5. Lip biopsy of accessory 
salivary glands was compatible with grade 1 according to Chisholm's 
classification. After ruling out the other granulomatous diseases 
such as tuberculosis, lymphoma, crohn's disease, Wegner 
granulomatosis..., the diagnosis of systemic sarcoisosis was 
ascertained. A short-course corticosteroid therapy with antimalarial 
drug were initiated with a favorable evolution both clinically and 
radiogically.The patient was presented in November 2011 with a 
history of intermittent palpitations and exertionaldyspnea of 4 
months duration, progressively worsening for 2 weeks before. She 
denied any history of hypertension, diabetes mellitus, coronary 
artery disease and thyroid disease. She did not smoke, consume 
alcohol, or illicit drugs. On physical examination, she was conscious, 
cooperative, and afebrile. She had a BP of 120/70 mmHg and a 
pulse of 160 beats/minute. There were no signs of cardiac failure; 
the rest of the physical examination did not reveal any abnormal 
findings. She was admitted to the cardiac intensive care unit. The 
admission ECG showed a ventricular tachycardia at 160 
cycles/minute. In the light of these typical symptoms and 
electrocardiographic alterations in a patient having systematic 
sarcoidosis, the diagnosis of sarcoidosis with cardiac involvement 
was suspected. The echocardiography showed a FE of 50%, bright 
shadows consisting with infiltration in the basal and inferoseptal 
ventricular myocardium, and moderate mitral regurgitation. 
Coronary angiography revealed normal coronary arteries. The 
cardiac electrophysiology study showed a monomorphic ventricular 
tachycardia induced by isoproterenol. Laboratory tests showed no 
relevant alterations in myocardial necrosis biomarkers, blood cell 
count, renal and liver function, or electrolytes. Given the absence of 
primary heart disease that would explain the cardiac abnormalities 
and especially the previous diagnosis of systemic sarcoidosis, the 
final diagnosis was sarcoidosis with cardiac involvement. The patient 
started with a dose of 1 mg/kg/day of corticosteroid, in addition to 
supportive care. Over 8 months, the steroids were tapered to a dose 
of 10 mg/day. Anti arrhythmic drug therapy (Amiodarone) and β 
blocker were initiated. Given the recurrent ventricular tachycardia 
with amiodarone, we proceeded to the implantation of an 
automated implantable cardioverter-defibrillator (ICD). Evolution 
was favorable.  
  




Sarcoidosis is a multisystemic disorder of unknown etiology which is 
characterized by the formation of non-caseating granulomas in 
involved tissues. To this day, it remains something of enigma, the 
search for an etiologic agent is ongoing [2]. Sarcoidosis can be 
widespread or limited to involvement of only a single system at a 
time, it most commonly involves the lungs, the lymph nodes of the 
thorax and the eye, despite the fact that virtually no organ systems 
are immune to infiltration by sarcoid granulomas. Cardiac 
involvement is one of the least common manifestations and it can 
occur at any point of time during the course of sarcoidosis. Vishal S 
et al reported that the incidence of clinical heart involvement was as 
approximately 5%, wheras at autopsy, the incidence was 
considerably higher (20 to 25%) [2].  
  
Making a diagnosis of cardiac sarcoidosis remains one of the main 
challenges in the management of the disease: in fact, if cardiac 
manifestations occur in patients with multisystemic sarcoidosis, the 
diagnosis, although circumstancial, is strongly suspected, which is in 
keeping with our 2 cases. However, when cardiac dysfunction is the 
only manifestation of sarcoidosis, the diagnosis is frequently not 
entertained. Clinical manifestations of cardiac sarcoidosis, ranging 
from asymptomatic conduction abnormalities to fatal ventricular 
arrhythmia or sudden death, are dependent on both the profusion 
and location of granulomas. Granulomas can involve the left 
ventricular free wall, basal ventricular septum, right ventricle, 
papillary muscle, right atrium, and left atrium [3]. Main relevant 
signs include complete heart block, ventricular tachycardia, supra 
ventricular arrhythmias (atrial flutter, fibrillation and paroxysmal 
atrial tachycardia), congestive heart failure, and sudden death. 
Other clinical manifestations may involve chest pain, 
electrocardiographic changes, and pericardial abnormalities 
(pericardial effusion, constrictive pericarditis, tamponade) [2]. 
Despite the fact that endomyocardial biopsy is theoretically the most 
confident mean to assert the diagnosis of cardiac sarcoidosis, it is 
an invasive procedure which lacks sensitivity: cardiac involvement 
tends to be patchy and granulomas are more likely to be located in 
the left ventricle and basal ventricular septum than in the right 
ventricle where endomyocardial biopsies are usually performed [4]. 
Thus, serial ECG during evolution survey, echocardiography, 24-h 
Holter monitoring of ECG, MRI with gadolinium contrast, 
technetium99m-sestamibi scintigraphy myocardial perfusion study, 
and coronary angiography can be helpful tools for diagnosis. 
However, all these complementary exams lack specificity for the 
disease [5]. Thus, in 1993, guidelines for the diagnosis of cardiac 
sarcoidosis have been published by the Japanese Ministry of Health 
and Welfare [6]. The 2 cases presented fulfill the diagnostic criteria 
set out in these guidelines (Table 1): cardiac abnormalities in the 
absence of primary heart disease with a previous diagnosis of 
intrathoracic sarcoidosis in the first case and Löfgren's syndrome in 
the second case. The clinical response to the treatment prescribed 
also supports our diagnosis suspicion.  
  
Considering the increased risk of sudden death, cardiac sarcoidosis 
is an indication for early treatment. Steroids should be started as 
soon as possible: many reports showed that, in early or middle 
stage disease, steroid therapy may be protective or therapeutic but 
may not be as effective in the late stages [7]. In both our cases, 
treatment was started at the middle stage of the disease and a 
favorable response was noted.The recommended starting dose 
seems to be 60 to 80 mg a day of prednisone, it can be tapered 
over 6 months to a dose of 10 mg a day [2]. Antiarrhythmic drugs 
and β blockers are also usually used in the management of cardiac 
sarcoidosis. To our knowledge, there have been no prospective 
studies evaluating the use of these medications in patients having 
cardiac sarcoidosis. Amiodarone can be responsible for the 
occurrence of pulmonary fibrosis. These drug-induced pulmonary 
changes, which are indistinguishable radiographically from 
pulmonary sarcoidosis, may threaten the patient's respiratory 
status. Consequently, we must carefully and constantly assess the 
potential benefits and risks of prescribing such medications. 
Regarding the treatment with ICD, it seems necessary in patients 
with refractory ventricular tachyarrhythmia who are at risk of 
sudden death in addition to antiarrhythmic drugs.  
  
Some authors recommended ICD implantation in any patient with 
sarcoidosis and non-sustained ventricular tachyarrhythmia because 
of the high rate of recurrence of ventricular tachycardia despite 
medical treatment [8, 9]. As for cardiac transplantation, it is rare 
and remains the only possibility for younger patients with severe 
and stage irreversible cardiac failure or resistant VT [10]. The 
prognosis of cardiac sarcoidosis remains obscure: early necropsy 
series concluded that survival in most patients with symptomatic 
cardiac sarcoidosis was limited to about 2 years [3], while better 
outcomes were noted in other series where 5-year survival rate was 
40-60%. Whether this improvement in prognosis was due to early 
disease recognition or a milder form of cardiac sarcoidosis versus 
early institution of medication remains to be determined. With 
progress in prevention and treatment of ventricular arrhythmias, the 
primary cause of death in cardiac sarcoidosis has changed from 





Cardiac sarcoidosis should always be suspected in any patient who 
is younger than expected presenting with cardiac symptoms without 
evidence of primary heart disease particularly if he has already been 
diagnosed with sarcoidosis. To date, early diagnosis of cardiac 
sarcoidosis remains a challenge because clinical manifestations are 
non specific and the diagnostic modalities lack sensitivity and 
specificity in spite of recent advances. A negative endomyocardial 
biopsy should in no way be regarded as evidence of absence of 
cardiac sarcoidosis, especially if diagnostic suspicion is strong. 
Cardiac sarcoidosis is on occasion a medical emergency that may 
lead to sudden death due to the rhythm disturbances or progressive 
heart failure from a dilated cardiomyopathy; therefore, in addition to 
corticosteroid treatment, early consideration for implantation of an 
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Table and figures 
 
Table 1: the Japanese Ministry of Health and Welfare 1993 
guidelines for the diagnosis of cardiac sarcoidosis  
Figure 1: cardiac magnetic resonance imaging (MRI) with 
gadolinium contrast: evidence of delayed hyper enhancement 
(arrow) in both the basal and inferolateral left ventricular regions  
Page number not for citation purposes 4 
Figure 2: decreased uptake in the inferolateral and apical 
ventricular myocardium, which was reversible during stress (reverse 
distribution) shown on Technetium99m sestamibiscintigraphy 
myocardial perfusion study  
Figure 3: high-resolution computed tomography scan of the chest 
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Cardiac sarcoid is confirmed then endomyocardial biopsy demonstrates epithelioid granulomas 
without caseating necrosis. 
2: clinical diagnosis 
group 
in patients with a histologic diagnosis of extracardiac sarcoidosis, cardiac sarcoidosis is suspected 
when: 
“a” and at least one of criteria “b” to “e” is present, and other etiologies such as hypertension and 
coronary artery disease have been excluded.  
a 
Bundle branch block, heart block of any degree, left-axis deviation, ventricular tachycardia, 
premature ventricular contraction, or pathological Q or ST-T change on resting or  ambulatory 
electrocardiogram.  
b Abnormal wall motion, regional wall thinning, or dilation of the left ventricle. 
c 
Perfusion defect by thallium.201 or technetium-99m myocardial scintigraphy, or abnormal 
accumulation by gallium 67.  
d 
Abnormal intracardiac pressure, low cardiac output, or abnormal wall motion or depressed ejection 
fraction of the left ventricle on cardiac catheterization.  
e 
Interstitial fibrosis or more than moderate cellular infiltration over moderate grade on 
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Figure 1: cardiac magnetic resonance imaging (MRI) with gadolinium contrast: evidence of 






Figure 2: decreased uptake in the inferolateral and apical ventricular myocardium, which was 
reversible during stress (reverse distribution) shown on Technetium99m sestamibiscintigraphy 
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Figure 3: high-resolution computed tomography scan of the chest showing peribronchial and bilateral hilar lymphadenopathy (arrows) 
 
 
 
 
 
